LADENBURG THALM/SH SH reiterated their buy rating on shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE) in a research note published on Monday, May 6th, AnalystRatings.com reports. They currently have a $26.00 price objective on the stock.
“We continue to look for Zygel’s NDA filing in 1H’20 and approval in 2H’20 as we had anticipated this Fast Track designation.”,” LADENBURG THALM/SH SH’s analyst commented.
ZYNE has been the topic of several other research reports. ValuEngine raised Zynerba Pharmaceuticals from a hold rating to a buy rating in a research report on Tuesday, April 30th. Zacks Investment Research raised Zynerba Pharmaceuticals from a hold rating to a buy rating and set a $7.00 price target on the stock in a research report on Friday, March 22nd. HC Wainwright reaffirmed a buy rating on shares of Zynerba Pharmaceuticals in a research report on Monday, March